Today: 6 November 2025
Subscribe
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones
 ·  ·  ·  ·  · 

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

by
16 October 2025
  • Stock action: Femasys (NASDAQ: FEMY) jumped roughly 46% on Oct. 16, 2025, trading around $0.80 by mid-day [1] [2]. (Previous close: $0.55). This spike followed news of the company’s upcoming fertility trade-show exhibition and broader industry catalysts.
  • Key event: Femasys will exhibit at ASRM 2025 (Oct 25–29) in San Antonio, showcasing its new FemaSeed® Intratubal Insemination fertility treatment [3]. CEO Kathy Lee-Sepsick said, “We are excited to return to ASRM to share our next-generation… FemaSeed® Intratubal Insemination,” underlining the company’s focus on reproductive therapies [4].
  • Regulatory wins – FemBloc®: Femasys’ non-surgical birth control device FemBloc won key approvals in 2025. It received a CE Mark in Europe (June 2025), MHRA approval in the UK (Aug 2025) [5], and MEDSAFE approval in New Zealand (Sept 2025) [6]. These endorsements make FemBloc the first in-office, non-surgical permanent birth control available in those regions.
  • First sales & partnerships: Following EU approval, Femasys sold its first European order (~$400,000) of FemBloc to Spanish partners in mid-2025 [7]. In late Sept. the company announced a partnership with Kebomed to distribute FemBloc in France and Benelux [8], further opening the largest European markets. Globally, new fertility product partnerships were also struck: in Sept. Femasys teamed with Medical Electronic Systems (MES) to launch a FemSperm™ Analysis Kit – completing its suite of in-office sperm-prep tools for FemaSeed treatment [9]. (In August it debuted the FemSperm Setup Kit and Prep Kit for gynecologists.)
  • Other developments: Earlier this year Femasys announced Australian/New Zealand approvals for its FemaSeed infertility product and FemVue diagnostic [10], and a U.S. clinic partnership (Carolinas Fertility Institute) to roll out FemaSeed at eight locations [11]. In August it priced an $8.0 million stock financing to fund commercialization [12] (closing soon after) and reported Q2 2025 revenue of $0.409M (+85% YoY) with a smaller-than-expected net loss ($0.16/share vs. –$0.18 est.) [13].

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination [14] [15]. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery [16] [17].

This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected US policy to expand IVF access, which analysts say has indirectly boosted Femasys’ profile. By midday on Oct. 16, FEMY was up about 46% at roughly $0.80 [18] [19] (well above its 52-week low ~$0.31 [20]). (Intraday, GuruFocus.com noted a 30% jump to $0.72 amid the IVF news, reflecting high volatility.)

Financials: Femasys is still unprofitable with a small market cap (~$30M) and past-year losses. In Q2 2025 it reported $0.41M sales (vs. $0.22M year-ago) and a net loss of $4.59M (−$0.16/share), about flat with 2024 [21]. Cash on hand was only $3.2M at Q2-end, though the recent $8M financing (Aug) will extend its runway [22]. The company expects this funding to “ramp commercialization of our FemaSeed® and FemBloc® offerings” [23].

Analyst views: Wall Street opinions are mixed. Online consensus remains bullish: for example, StockAnalysis.com shows a “Strong Buy” consensus and an average 12-month target of $7.33 (an 800%+ upside from current levels) [24]. TipRanks similarly cites an average target of about $3.83 (≈550% upside) [25]. By contrast, Weiss Ratings in early Oct. reiterated a “Sell (E+)” grade on FEMY [26]. MarketBeat notes that 3 analysts rate Femasys a Buy and 1 a Sell, giving an overall “Moderate Buy” consensus [27]. HC Wainwright (a regular coverage firm) last week trimmed its target to $8.00 (from $12) but kept a Buy rating [28].

In summary, Femasys is trading on recent product and regulatory progress. The stock’s Oct. 16 rally reflects excitement over its fertility-technology milestones (IVF-related news and ASRM expo) [29] [30]. However, analysts caution that the company still faces financial challenges (high losses, funding needs) [31]. Looking ahead, key watchpoints include further FDA updates (the pivotal “FINALE” trial for FemBloc is enrollingpatients [32] [33]), upcoming sales of FemBloc in Europe, and Femasys’ Q3 results. For now, price targets range widely. As one analyst summary put it, investors are weighing Femasys’ “next-generation infertility innovation” against its cash burn and market risks [34] [35].

Sources: Femasys press releases and SEC filings [36] [37]; Market data from Investing.com and MarketBeat [38] [39]; analyst reports (MarketBeat, StockAnalysis, TipRanks) [40] [41] [42]; industry news outlets.

References

1. www.marketbeat.com, 2. www.investing.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. ir.femasys.com, 6. ir.femasys.com, 7. ir.femasys.com, 8. ir.femasys.com, 9. www.stocktitan.net, 10. ir.femasys.com, 11. ir.femasys.com, 12. www.stocktitan.net, 13. ir.femasys.com, 14. www.globenewswire.com, 15. www.stocktitan.net, 16. ir.femasys.com, 17. ir.femasys.com, 18. www.marketbeat.com, 19. www.investing.com, 20. www.investing.com, 21. ir.femasys.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. stockanalysis.com, 25. www.tipranks.com, 26. www.americanbankingnews.com, 27. www.americanbankingnews.com, 28. www.americanbankingnews.com, 29. www.globenewswire.com, 30. www.marketbeat.com, 31. www.gurufocus.com, 32. www.globenewswire.com, 33. ir.femasys.com, 34. www.globenewswire.com, 35. www.americanbankingnews.com, 36. ir.femasys.com, 37. ir.femasys.com, 38. www.marketbeat.com, 39. www.investing.com, 40. www.americanbankingnews.com, 41. stockanalysis.com, 42. www.tipranks.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. Palantir (PLTR) slips ~5.7% as new marketing & smart‑city deals land — What’s moving the stock today (Nov. 6, 2025)
  2. Oracle (ORCL) Stock Today — November 6, 2025: Price Slides as AI-Spend Scrutiny Builds; Fresh AI Database Coverage, Gartner ‘Leader’ Nod, and New OCI Partnerships in Focus
  3. Meta (META) Stock Today: Shares Slip ~2% as Reuters Probes Scam Ads and MPA Challenges Instagram’s ‘PG‑13’ Claim — Nov 6, 2025
  4. Tesla Stock Today (Nov 6, 2025): TSLA Slides as Shareholders Vote on Elon Musk’s $1T Pay Package; Cybertruck Order Shift Adds Fresh Jitters

Stock Market Today

  • Gogo (GOGO) Beats Q3 Earnings and Revenue Estimates Amid Mixed Outlook
    November 6, 2025, 12:40 PM EST. Gogo (GOGO) reported Q3 earnings of $0.10 per share, topping the Zacks Consensus of $0.07 and marking a +42.86% surprise from the quarter. Revenue reached $223.59 million, slightly above the consensus by 0.2%, up from $100.53 million a year earlier. The company has surpassed EPS estimates in all four of the last four quarters. Management commentary on the upcoming earnings call will be crucial to gauge the sustainability of the move, as the stock has gained about 8.3% year-to-date versus the S&P 500's 15.6% gain. The current Zacks Rank remains #3 Hold, with near-term estimates for next quarter at $0.05 on $226.45 million in revenue and the current fiscal year at $0.30 on $905.94 million in revenue. Industry expectations for Wireless National remain a headwind.
  • C4 Therapeutics Q3 Loss Narrower, Revenue Beats Estimates; Zacks Rank Up (Buy)
    November 6, 2025, 12:37 PM EST. C4 Therapeutics (CCCC) posted Q3 loss of $0.44 per share, better than the Zacks consensus of a $0.47 loss and up from $0.35 a year ago (adjusted for non-recurring items), delivering an earnings surprise of +6.38%. Revenue came in at $11.23 million, topping the consensus by 72.77% and down from $15.36 million a year earlier. The stock has shed about 34.2% this year, underperforming the S&P 500's 15.6% gain. On the outlook, near-term estimates were favorable going into the print, and C4 remains rated Zacks Rank #2 (Buy), with current consensus for the next quarter at -$0.29 on $9.5 million in revenues and -$1.46 on $29.7 million for the full year. Investors will await management commentary on the earnings call.
  • Microsoft Stock Split: Is a Dow-Linked Move Imminent?
    November 6, 2025, 12:32 PM EST. Microsoft could be eyeing a stock split to ease its impact on the Dow Jones Industrial Average, a price-weighted index where MSFT wields outsized influence. With shares around the mid- to high-$400s, a split would keep the stock from creeping toward four figures and help maintain Dow eligibility among its 30 components. The case strengthens as Satya Nadella has steered the company into a cloud- and AI-driven growth era, lifting the stock since 2014 after the Ballmer era. Not since 2003 has MSFT split, and the market's structure-rather than the business itself-could motivate action before pricing milestones. Watch for signals from Microsoft leadership or Dow index committees.
  • Titan International Q3 Revenue Beats, but Q4 Guidance Falls Short
    November 6, 2025, 12:31 PM EST. Titan International (NYSE:TWI) reported Q3 CY2025 revenue of $466.5 million, up 4.1% YoY and ahead of $458.9 million consensus (1.7% beat). GAAP EPS was -$0.04, vs -$0.03 expected, a $0.01 miss, while adjusted EBITDA reached $29.77 million on a 6.4% margin, an 11.1% beat. The company guided Q4 revenue at $397.5 million midpoint, below consensus of $420.7 million, and EBITDA at $10 million vs $16.48 million. Operating margin rose to 2.1% from 0.9% YoY; free cash flow margin slipped to 6.4% from 9.3%. Market cap is about $508 million. In a cyclical Agricultural Machinery backdrop, Titan faces growth headwinds but has shown some resilience in product demand.
  • AI Productivity Could Push Retirement Withdrawals Beyond 8% with Dividend-Focused CEFs
    November 6, 2025, 12:28 PM EST. Retirees could safely withdraw 8% or more from portfolios thanks to AI-driven productivity, revisiting the historic withdrawal rule. Since William Bengen's 1994 4% rule, research has nudged the safe rate higher to about 4.7% as tech and markets improved. Over the last 30 years the S&P 500 delivered roughly 11.7% annualized total return, helping portfolios keep pace with inflation. Today, AI-enabled productivity is powering corporate earnings and could broaden the withdrawal window. Some investors favor a dividend-focused closed-end fund strategy, using vehicles like the Adams Diversified Equity Fund (ADX) for higher income and potential dividend growth, while letting capital grow as AI boosts productivity. The plan: aim for robust income via dividends, with growth from equities.
Beyond Meat Stock CRASH: 60% Plunge After Shocking Debt Swap Stuns Investors
Previous Story

Beyond Meat Shares Plunge as Debt Restructure Sparks Panic

Up 150% YTD: Navitas Semiconductor (NVTS) Rides the GaN Power Wave into AI’s Future
Next Story

Navitas (NVTS) Stock Hits All-Time High on NVIDIA AI Chip News – Will the Rally Continue?

Related Articles

Go toTop